Search results for " doxorubicin."

showing 10 items of 41 documents

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone ly…

2015

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%).…

MaleCancer ResearchBiopsymedicine.medical_treatmentfirst lineKaplan-Meier EstimateSplenic marginal zone lymphoma; first line; rituximabPolyethylene GlycolGastroenterologyPolyethylene GlycolsrituximabBone MarrowPrednisonefirst line; rituximab; splenic marginal zone lymphomaCause of DeathAntineoplastic Combined Chemotherapy ProtocolsSplenic marginal zone lymphomaAged 80 and overHematologyMiddle AgedPrognosisCombined Modality TherapySplenic NeoplasmTreatment OutcomeItalyOncologyVincristineFemaleRituximabHumanmedicine.drugAdultmedicine.medical_specialtyVincristineLymphoma B-CellCyclophosphamidePrognosiSplenectomySplenic NeoplasmNeutropeniaImmunophenotypingfirst line; rituximab; Splenic marginal zone lymphoma; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Italy; Kaplan-Meier Estimate; Lymphoma B-Cell; Male; Middle Aged; Polyethylene Glycols; Prednisone; Prognosis; Rituximab; Splenic Neoplasms; Treatment Outcome; Vincristine; Hematology; Oncology; Cancer ResearchInternal medicinemedicineHumansSplenic marginal zone lymphomaCyclophosphamideAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industrySplenic NeoplasmsBiomarkermedicine.diseaseSurgeryDoxorubicinPrednisonebusinessBiomarkers
researchProduct

R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted …

2013

Purpose Although rituximab (R) is commonly used for patients with advanced follicular lymphoma (FL) requiring treatment, the optimal associated chemotherapy regimen has yet to be clarified. Patients and Methods We conducted an open-label, multicenter, randomized trial among adult patients with previously untreated stages II to IV FL to compare efficacy of eight doses of R associated with eight cycles of cyclophosphamide, vincristine, and prednisone (CVP) or six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or six cycles of fludarabine and mitoxantrone (FM). The principal end point of the study was time to treatment failure (TTF). Results There were 534 patients…

MaleCancer ResearchLymphomamedicine.medical_treatmentFollicular lymphomaCHOPGastroenterologyAntineoplastic Combined Chemotherapy ProtocolsProspective StudiesLymphoma FollicularNON-HODGKINS-LYMPHOMASAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; Vincristine; Oncology; Cancer ResearchCHEMOTHERAPYMiddle AgedPrognosisChemotherapy regimenFludarabineSurvival RateOncologyVincristineFemaleFLUDARABINECLINICAL-TRIALSVidarabinemedicine.drugAdultVincristinemedicine.medical_specialtyAdult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubicin; Female; Follow-Up Studies; Humans; Lymphoma Follicular; Male; Middle Aged; Mitoxantrone; Neoplasm Grading; Neoplasm Staging; Prednisone; Prognosis; Prospective Studies; Survival Rate; Vidarabine; VincristineInternal medicinemedicineHumansRITUXIMABSurvival rateCyclophosphamideRESPONSE CRITERIAAgedNeoplasm StagingChemotherapyMitoxantronebusiness.industryFollicularmedicine.diseasePHASE-IIISurgery1ST-LINE TREATMENTDoxorubicinPrednisoneMitoxantroneNeoplasm GradingbusinessFollow-Up StudiesJournal of clinical oncology : official journal of the American Society of Clinical Oncology
researchProduct

General oxidative stress during doxorubicin-induced cardiotoxicity in rats: Absence of cardioprotection and low antioxidant efficiency of alpha-lipoi…

2012

International audience; To evaluate the effects of alpha-lipoic acid (AL) in a model of doxorubicin (DOX)-induced cardiotoxicity, male Wistar rats were treated with DOX (1 mg/kg/d; 10 d) in combination or not with AL (50 mg/kg/d; 15 d). Plasma oxidative stress was determined by hydroperoxides (ROOH) and the ascorbyl radical/ascorbate ratio. One and two months later, the functional parameters of the hearts were determined in vivo by catheterization and cardiac oxidative stress was assessed by malonedialdehyde (MDA) and O₂*⁻ (dihydroethidium fluorescence) content in tissue. After two months, body weight was higher in the DOX-AL group than in DOX (+16%), but this was due to ascites. Histologic…

MaleMESH : Oxidative StressAntioxidantmedicine.medical_treatmentMESH : HematocritMESH : Thioctic AcidBiochemistryAntioxidants0302 clinical medicineSuperoxidesAscitic FluidMESH: AnimalsMESH : Body WeightComputingMilieux_MISCELLANEOUS0303 health sciencesThioctic AcidCumulative doseMESH: Heart DiseasesHeartGeneral Medicine3. Good healthMESH: Ascitic Fluid[SDV] Life Sciences [q-bio]030220 oncology & carcinogenesisMESH : Ascitic FluidMESH: Hydrogen PeroxideMESH : AntioxidantsMESH: Thioctic Acidmedicine.medical_specialtyCardiotonic AgentsCardiotoxinsMESH: Hematocrit03 medical and health sciencesMESH: Doxorubicin[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIn vivoRats Wistar[ SDV ] Life Sciences [q-bio]MyocardiumMESH: AntioxidantsHydrogen PeroxideMESH: Cardiotonic AgentsMESH : Organ SizeMESH: Body WeightMESH: Heartcarbohydrates (lipids)EndocrinologyMESH: LiverMESH : SuperoxidesMESH: Organ Size[SDV]Life Sciences [q-bio]MESH : Cardiotonic AgentsAscorbic AcidMESH: Superoxidesmedicine.disease_causeMESH: EatingEatingpolycyclic compoundsMESH : MyocardiumMESH: Thiobarbituric Acid Reactive SubstancesMESH: Ascorbic AcidAntibiotics AntineoplasticMESH: Oxidative StressChemistryMESH : RatsOrgan SizeMESH : Antibiotics Antineoplastic[SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemBiochemistryHematocritLiverMESH : Cardiotoxinsmedicine.drugMESH : EatingMESH: MyocardiumHeart DiseasesMESH: RatsMESH : MaleMESH : Thiobarbituric Acid Reactive SubstancesMESH : Rats WistarThiobarbituric Acid Reactive SubstancesContractilityMESH : HeartInternal medicinemedicineTBARSAnimalsMESH : DoxorubicinDoxorubicinMESH: Antibiotics AntineoplasticMESH : Ascorbic Acid030304 developmental biologyCardiotoxicityBody WeightMESH : LiverMESH : Heart DiseasesMESH: Rats WistarMESH: MaleRatsOxidative StressMESH: CardiotoxinsDoxorubicinMESH : AnimalsMESH : Hydrogen PeroxideOxidative stress
researchProduct

Stacking as a key property for creating nanoparticles with tunable shape: The case of squalenoyl-doxorubicin

2019

The development of elongated nanoparticles for drug delivery is of growing interest in recent years, due to longer blood circulation and improved efficacy compared to spherical counterparts. Squalenoyl-doxorubicin (SQ-Dox) conjugate was previously shown to form elongated nanoparticles with improved therapeutic efficacy and decreased toxicity compared to free doxorubicin. By using experimental and computational techniques, we demonstrate here that the specific physical properties of SQ-Dox, which include stacking and electrostatic interactions of doxorubicin as well as hydrophobic interactions of squalene, are involved in the formation of nanoassemblies with diverse elongated structures. We …

Materials scienceStackingGeneral Physics and AstronomyNanoparticleAntineoplastic AgentsNanotechnology02 engineering and technologysqualene010402 general chemistry01 natural sciencesbioconjugate; cylindrical nanoparticles; doxorubicin; elongated nanoparticles; nanomedicine; squalene; stackingdoxorubicinHydrophobic effectDrug Delivery Systemselongated nanoparticlespolycyclic compoundsGeneral Materials Sciencebioconjugatecylindrical nanoparticlesBioconjugationGeneral Engineering021001 nanoscience & nanotechnologynanomedicine3. Good health0104 chemical sciencesIonic strengthstackingDrug deliveryNanoparticlesNanomedicine0210 nano-technologyHydrophobic and Hydrophilic InteractionsConjugateACS Nano
researchProduct

Amphiphilic inulin graft co-polymers as self assembling micelles for doxorubicin delivery

2020

This paper reports the synthesis and characterization of a new amphiphilic inulin graft copolymer able to self-assemble in water into a micelle type structure and to deliver the anticancer model drug doxorubicin. For this aim, inulin was chemically modified in the side chain with primary amine groups (INU-EDA) and these were used as reactive moieties for the conjugation of poly ethylene glycol 2000 and succinyl-ceramide. The CMC of obtained amphiphilic inulin derivatives (INU-ceramide and INU-ceramide-PEG2000) was measured by means of fluorescence analysis using pyrene as the fluorescent probe. The obtained micelles were characterized by DLS and AFM analysis and the ability to release the l…

Materials sciencemicellesInulinBiomedical EngineeringMicelledoxorubicinchemistry.chemical_compoundPolymer chemistryAmphiphileCopolymermedicineSide chainGeneral Materials ScienceDoxorubicininulin micelles drug delivery doxorubicin graft co-polymersgraft co-polymersinulinGeneral ChemistryGeneral MedicinechemistrySettore CHIM/09 - Farmaceutico Tecnologico ApplicativoDrug deliverydrug deliveryPyrenemedicine.druginulin; micelles; drug delivery; doxorubicin; graft co-polymers
researchProduct

Pegylated liposomal doxorubicin in the management of ovarian cancer

2014

Ovarian cancer is the leading cause of death among gynecological tumors. Carboplatin/paclitaxel represents the cornerstone of front-line treatment. Instead, there is no consensus for management of recurrent/progressive disease, in which pegylated liposomal doxorubicin (PLD) ± carboplatin is widely used. We performed a systematic review and metaanalysis to evaluate impact of PLD-based compared with no-PLD-based regimens in the ovarian cancer treatment. Data were extracted from randomized trials comparing PLD-based treatment to any other regimens in the January 2000-January 2013 time-frame. Study end-points were overall survival (OS), progression free survival (PFS), response rate (RR), CA125…

MetaanalysiOncologyCancer Researchmedicine.medical_specialtyendocrine system diseasesPharmacologyarian cancerDisease-Free SurvivalPolyethylene Glycolslaw.inventionchemistry.chemical_compoundRandomized controlled triallawOvPegylated liposomal doxorubicinInternal medicinemedicineHumansProgression-free survivalSystemic chemotherapyProportional Hazards ModelsRandomized Controlled Trials as TopicOvarian NeoplasmsPharmacologyAntibiotics Antineoplasticbusiness.industryProportional hazards modelHazard ratiomedicine.diseaseCarboplatinTreatment OutcomeOncologychemistryTolerabilityDoxorubicinClinical StudyMolecular MedicineFemaleRandomized clinical trialbusinessOvarian cancerProgressive diseaseCancer Biology & Therapy
researchProduct

Interaction of Doxorubicin with Polynucleotides. A Spectroscopic Study

2014

The interaction of doxorubicin (DX) with model polynucleotides poly(dG-dC)·poly(dG-dC) (polyGC), poly(dA-dT)·poly(dA-dT) (polyAT), and calf thymus DNA has been studied by several spectroscopic techniques in phosphate buffer aqueous solutions. UV-vis, circular dichroism, and fluorescence spectroscopic data confirm that intercalation is the prevailing mode of interaction, and also reveal that the interaction with AT-rich regions leads to the transfer of excitation energy to DX not previously documented in the literature. Moreover, the DX affinity for AT sites has been found to be on the same order of magnitude as that reported for GC sites.

Models MolecularCircular dichroismStereochemistryPolynucleotidesIntercalation (chemistry)polinucleotidi; spettroscopia; doxorubicinaBiochemistrychemistry.chemical_compoundSpectrophotometrymedicineAnimalsMoleculeAqueous solutionMolecular Structuremedicine.diagnostic_testChemistryCircular DichroismDNAFluorescenceCrystallographySpectrometry FluorescenceDoxorubicinPolynucleotideCattleSpectrophotometry UltravioletDNABiochemistry
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Glutathione-sensitive nanogels for drug release

2014

Nanogels (NGs) synthesized by pulsed electron-beam irradiation of semi-dilute poly (N-vinyl pyrrolidone) (PVP) aqueous solutions, at relatively low energy per pulse and doses within the sterilization dose range, represent a very interesting family of polymeric nanocarriers. Ionizing irradiation-induced crosslinking of PVP allows to control particle size, and surface chemistry of the polymer nanoparticles without making use of catalysts, organic solvents or surfactants, and with beneficial effects onto the purity and hence biocompatibility of the final products obtained. Furthermore, the availability of reactive functional groups, either generated by the radiation or purposely grafted via co…

NanogelDoxorubicinNanogels; drug delivery; Doxorubicindrug deliverySettore CHIM/07 - Fondamenti Chimici Delle Tecnologie
researchProduct

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer. Preliminary activity results of the MITO-2 phase III trial

2008

<i>Background:</i> Based on the efficacy of pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer, we are conducting a phase III study comparing carboplatin plus either paclitaxel or PLD as first-line therapy in advanced ovarian cancer. Because of limited phase I and II data on PLD plus carboplatin in this setting, we conducted an interim activity analysis. <i>Patients and Methods:</i> Patients with stage 1c-IV epithelial ovarian cancer were randomized to carboplatin AUC 5 plus either paclitaxel 175 mg/m<sup>2</sup> or PLD 30 mg/m<sup>2</sup> every 3 weeks for 6 cycles. The interim activity analysis was planned according to a single…

Oncologyarea under curveCancer Researchendocrine system diseasesmedicine.medical_treatmentneoplasmspolyethylene glycolsantibioticsPegylated Liposomal Doxorubicinsurvival analysischemistry.chemical_compoundpaclitaxelmiddle agedantineoplastic agentsNeoplasms Glandular and EpithelialhumansanthracyclinesAntibiotics AntineoplasticadultGeneral Medicineovarian neoplasmsfemale genital diseases and pregnancy complicationsagedovarian cancerfemaleOncologyPaclitaxelcarboplatinlipids (amino acids peptides and proteins)Anthracyclinesmedicine.drugmedicine.medical_specialtyantineoplasticantineoplastic combined chemotherapy protocolsglandular and epithelialdoxorubicinpegylated liposomal doxorubicinInternal medicineanthracyclines; carboplatin; ovarian cancer; paclitaxel; pegylated liposomal doxorubicin; adult; aged; antibiotics antineoplastic; antineoplastic agents; antineoplastic combined chemotherapy protocols; area under curve; carboplatin; doxorubicin; female; humans; middle aged; neoplasm staging; neoplasms glandular and epithelial; ovarian neoplasms; paclitaxel; polyethylene glycols; survival analysis; treatment outcomemedicineDoxorubicinneoplasm stagingAdvanced ovarian cancerChemotherapybusiness.industryCancermedicine.diseaseCarboplatinEndocrinologychemistrytreatment outcomebusinessOvarian cancer
researchProduct